Zobrazeno 1 - 10
of 76
pro vyhledávání: '"E Guiard"'
Autor:
M. LANKTREE, E. Guiard, P. Akbari, M. Pourafkari, I.A. Iliuta, S. Ahmed, A. Haghighi, N. He, X. Song, A. Paterson, K. Khalili, Y. Pei
Publikováno v:
Kidney International Reports, Vol 6, Iss 4, Pp S185-S186 (2021)
Externí odkaz:
https://doaj.org/article/353acb8d9e1c41f3a3198bc4a4aaef37
Autor:
P Blin, N Danchin, J Benichou, C Dureau-Pournin, E Guiard, D Sakr, J Jove, R Lassalle, C Droz-Perroteau, N Moore
Publikováno v:
European Heart Journal. 43
Background Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12-i (clopidorel, prasugrel or ticagrelor), is recommended for one year after myocardial infarction (MI) for secondary prevention of cardiovascular disease (SP-CVD). Beyond one year maint
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3255bc3e30a9200ca8eb8ead64d4e56
https://doi.org/10.1093/eurheartj/ehac544.1313
https://doi.org/10.1093/eurheartj/ehac544.1313
Autor:
P. Jourdain, P. Blin, P. Zaoui, E. Guiard, D. Sakr, M.-A. Bernard, C. Dureau-Pournin, R. Lassalle, F. Thomas-Delecourt, S. Bineau, N. Moore, C. Droz-Perroteau, M. Joubert
Publikováno v:
European Heart Journal. 43
Background Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal disease (CVRD) complications for type 2 diabetes (T2D). However, for those with a si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::564afd0efad4920258b4c33e6fb1fec3
https://doi.org/10.1093/eurheartj/ehac544.1306
https://doi.org/10.1093/eurheartj/ehac544.1306
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
P Blin, P Zaoui, M Joubert, E Guiard, D Sakr, C Dureau-Pournin, MA Bernard, R Lassalle, F Thomas-Delecourt, S Bineau, N Moore, C Droz-Perroteau, P Jourdain
Publikováno v:
Value in Health. 25:S173
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bd05e8bfcabe713e3abb6935aff74f8
https://doi.org/10.1016/j.jval.2022.09.839
https://doi.org/10.1016/j.jval.2022.09.839
Autor:
Francis Mégraud, Nicholas Moore, Régis Lassalle, Magali Rouyer, Cécile Droz-Perroteau, François Tison, Bertrand Diquet, Abdelilah Abouelfath, E. Guiard, Patrick Blin, Frank Zerbib
Summary Background Quadruple therapy using a single capsule formulation of bismuth, metronidazole and tetracycline (BMT; Pylera®), associated with omeprazole for the eradication of Helicobacter pylori, represents the reintroduction of bismuth in Fra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cb663db69df1fd7240e8a772a9a6366
http://hdl.handle.net/20.500.12278/26774
http://hdl.handle.net/20.500.12278/26774
Autor:
M. Monge, E. Guiard, S. Henriquez, T. Cochois, C. Richaud, M. Allouache, F. Compain, A. Gohari
Publikováno v:
Néphrologie & Thérapeutique. 18:330
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0480cc3532063ffe360ebe2d356e2b8c
https://doi.org/10.1016/j.nephro.2022.07.126
https://doi.org/10.1016/j.nephro.2022.07.126
Publikováno v:
Infectious Diseases Now
Nephrologie & Therapeutique
Nephrologie & Therapeutique
Introduction Les patients hemodialyses chroniques (HDC) sont a haut risque de developper une forme grave d’infection a SARS-CoV-2. Ils constituent une population cible pour la vaccination. Toutefois, la reponse vaccinale chez ces patients n’est p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6f09b0fcba4d73ed77c8b21a6b04cd0
http://europepmc.org/articles/PMC8327504
http://europepmc.org/articles/PMC8327504
Autor:
Régis Lassalle, Nicholas Moore, M.-A. Bernard, Cécile Droz-Perroteau, P Darmon, H. Maïzi, Caroline Dureau-Pournin, Patrick Blin, E. Guiard, P Henry, Florence Thomas-Delecourt
Publikováno v:
European Heart Journal. 41
Background The THEMIS randomized controlled trial showed that patients with stable coronary artery disease and type 2 diabetes mellitus (CAD-T2DM), without prior myocardial infarction (MI) or stroke, and who received ticagrelor plus aspirin, had a lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::823f1c49d43524ee88f009a6a14aaf80
https://doi.org/10.1093/ehjci/ehaa946.1348
https://doi.org/10.1093/ehjci/ehaa946.1348
Autor:
E. Guiard, Florence Thomas-Delecourt, H. Maïzi, Régis Lassalle, P Darmon, M.-A. Bernard, P Henry, Caroline Dureau-Pournin, Nicholas Moore, Patrick Blin, Cécile Droz-Perroteau
Publikováno v:
European Heart Journal. 41
Background The THEMIS randomized controlled trial showed that patients with stable coronary artery disease and type 2 diabetes mellitus (CAD-T2DM), without a history of myocardial infarction (MI) or stroke, and who received ticagrelor plus aspirin, h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b892824c8475537d02aa541eb9384d9
https://doi.org/10.1093/ehjci/ehaa946.1314
https://doi.org/10.1093/ehjci/ehaa946.1314